In addition to the specific organ criteria, transplant candidates must also meet the following general criteria, including, but not limited to:  Since compliance is a major factor in transplant graft survival, the patient (or legal guardian) must have the ability to accept and understand the transplant procedure and to maintain compliance with long-term medical management and immunosuppression.  If applicable, patients with a history of malignancy must have passed the recommended length of time to be considered cured for that specific cancer. A complete metastatic evaluation must be performed before a patient will be considered an acceptable transplant candidate.  Patients with a history of alcohol or substance abuse must have a six month history of abstinence as evidenced by negative urine or serum drug screens taken randomly.  The patient must have adequate cardiopulmonary status.  The patient must be free from active infection.
A covered person is eligible for retransplantation as deemed medically necessary and appropriate by BCBSKC. Review of a retransplantation request will include review of the covered person's compliance with relevant transplant selection criteria including, but not limited to, adherence to medication regimens, follow-up examinations and abstinence from the use of alcohol and drugs.
Clinical trials of cell transplantation for conditions other than those allowed in this policy may be available in the research setting. However, these trials are considered investigational and/or experimental and therefore contract exclusions.
Clinical trials for conditions other than those allowed in this policy may be available in the research setting. However, these trials are considered investigational and/or experimental and therefore contract exclusions 
Description of Procedure or Service
Autologous islet transplantation, performed in conjunction with pancreatectomy, is proposed to reduce the likelihood of insulin-dependent diabetes. Moreover, allogeneic islet cell transplantation is being investigated as a treatment or cure for patients with type 1 diabetes.
In autologous islet transplantation, during the pancreatectomy procedure, islet cells are isolated from the resected pancreas using enzymes, and a suspension of the cells is injected into the portal vein of the patient's liver. Once implanted, the beta cells in these islets begin to make and release insulin. In the case of allogeneic islet cell transplantation, cells are harvested from the deceased donor's pancreas, processed, and injected into the recipient's portal vein. Up to 3 donor pancreas transplants may be required to achieve insulin independence. Allogeneic transplantation may be performed in the radiology department.
Chronic Pancreatitis
Primary risk factors for chronic pancreatitis include toxic-metabolic, idiopathic, genetic, autoimmune, recurrent and severe acute pancreatitis, or obstructive (the TIGAR-O classification system). Patients with chronic pancreatitis may experience intractable pain that can only be relieved with a total or near total pancreatectomy. However, the pain relief must be balanced against the certainty that the patient will be rendered an insulin-dependent diabetic. Autologous islet transplantation has been investigated as a technique to prevent this serious morbidity.
Type 1 Diabetes
Allogeneic islet transplantation has been used for type 1 diabetes to restore normoglycemia and, ultimately, reduce or eliminate the long-term complications of diabetes such as retinopathy, neuropathy, nephropathy, and cardiovascular disease. Islet transplantation potentially offers an alternative to wholeorgan pancreas transplantation. However, a limitation of islet transplantation is that 2 or more donor organs are usually required for successful transplantation, although experimentation with single-donor transplantation is occurring. A pancreas that is rejected for whole-organ transplant is typically used for islet transplantation. Therefore, islet transplantation is recommended only for patients with frequent and severe metabolic complications who have consistently failed to achieve control with insulin-based management.
In 2000, a modified immunosuppression regimen increased the success of allogeneic islet transplantation. This regimen was developed in Edmonton, Canada and is known as the "Edmonton protocol."
Regulatory Status
Islet cells are subject to regulation by the U.S. Food and Drug Administration (FDA), which classifies allogeneic islet cell transplantation as somatic cell therapy, requiring premarket approval. Islet cells also meet the definition of a drug under the federal Food, Drug, and Cosmetic Act. Clinical studies to determine safety and effectiveness outcomes of allogeneic islet transplantation must be conducted under FDA investigational new drug (IND) regulation. While at least 35 IND applications have been submitted to the FDA, no center has submitted a biologics license application.
Rationale
The policy was created in 2001 and was updated regularly with searches of the MEDLINE database. The most recent literature review was conducted through March 26, 2014. Following is a summary of the key literature to date on islet cell transplantation.
Chronic Pancreatitis
In 2012, Bramis et al published a systematic review of studies on islet transplantation after total pancreatectomy in patients with chronic pancreatitis.(1) The investigators searched for studies reporting on patients who had been treated with total, subtotal or completion pancreatectomy followed by islet autotransplantation. Case series were included if they included more than 5 patients and reported outcomes for consecutive patients. A total of 72 full-text articles were reviewed, and 5 studies were found to meet inclusion criteria. The postoperative insulin independence rate in the 5 studies ranged from 10% (mean follow-up, 8 years) to 46% (mean follow-up, 5 years). In the study with the longest follow-up, the insulin independence rate was 28% at 10 years. Two studies reported postoperative morphine use. In 1 study, patients reported a mean postoperative decrease in morphine use of 116 mg and in the other, a mean decrease of 55 mg of morphine was reported.
An earlier systematic review of studies on islet transplantation after pancreatectomy was published in 2011 by Dong et al. (2) Studies were included regardless of design or sample size. After reviewing 84 studies, 15 observational studies were found to meet eligibility criteria. There were 11 studies of total pancreatectomy, 2 studies of partial pancreatectomy, and 2 studies that included both types of surgery. Sample sizes in individual studies ranged from 3 to 173 patients. Thirteen studies included patients with chronic pancreatitis, and 2 included patients with benign pancreatic tumors. The pooled 30-day mortality was 5% (95% confidence interval [CI], 2% to 10%), and the cumulative mortality at 1 year (reported by 10 studies) was 4.9% (95% CI, 2.6% to 7.3%) In a pooled analysis of data from 14 studies, the rate of insulin dependence at last follow-up was 4.6 per 100 person years (95% CI, 1.53 to 7.62). The pooled rate of insulin independence at 1 year (5 studies) was 27% (95% CI, 21% to 33%) and at 2 years (3 studies) was 21% (95% CI, 16% to 27%).
Representative studies included in the systematic reviews or published more recently are described next.
A large single center series was reported by Sutherland et al in 2012. (3) The study included 409 patients with chronic pancreatitis who underwent total pancreatectomy and islet transplantation between February 1977 and September 2011. Fifty-three of the 409 patients (13%) were children between the ages of 5 and 18 years. Actuarial survival postsurgery was 96% in adults and 98% in children after 1 year and 89% in adults and 98% in children after 5 years. A total of 15.9% of patients experienced surgical complications requiring reoperation during the initial admission. The most common reason for reoperation was bleeding, occurring in 9.5% of patients. At 3 years, 30% of patients were insulin independent (25% of adults and 55% of children). A survey of quality-of-life outcomes was initiated in October 2008; responses were available for 102 patients. At baseline, all 102 patients reported using narcotics for pain. At 12 months, the proportion of patients on narcotics decreased to 56% (n=32), and at 24 months, 41% of respondents (n=21) reported using narcotics. 
Type 1 Diabetes
In April 2004, TEC completed an evidence report on islet cell transplantation in type 1 diabetes in its capacity as an Evidence-based Practice Center for the Agency for Healthcare Research and Quality. (6) The evidence report found that published data on clinical outcomes of islet-alone transplantation were limited by small patient numbers, few transplant centers, short duration of follow-up, and lack of standardized methods of reporting clinical outcomes. Rare, serious adverse events have occurred in patients given islet transplants; recent procedure modifications reportedly minimize risks of these adverse events. No procedure-related deaths, cytomegalovirus infection, or posttransplantation lymphoproliferative disease have been reported for islet-alone transplantation.
The 2008 report from the Collaborative Islet Transplant Registry (CITR), which collects and monitors data on allogeneic islet transplantation in North America, Europe, and Australia, had 325 adult recipients in their registry as of April 2008.(7) Three years after first infusion, 23% of islet-alone recipients were insulin independent (defined as insulin independent 2 or more weeks), 29% were insulin dependent with detectable C-peptide, 26% had lost function, and 22% had missing data. Seventy percent achieved insulin independence at least once, 71% of whom were still insulin independent 1 year later and 52% at 2 years. Factors that favored primary outcomes were higher number of islet infusions, greater number of total islet equivalents infused, lower pretransplant HbA 1c levels, processing centers related to the transplant center, and larger islet size. The CITR published an updated report in 2012; the focus of the article was changes in outcomes over time. In 2011, Thompson et al in Canada published findings from a prospective crossover study of intensive medical therapy (pretransplant) versus islet cell transplantation in patients with type 1 diabetes. (9) The article reported on 45 patients; at the time of data analysis, 32 had received islet cell transplants. Median follow-up was 47 months pretransplant and 66 months posttransplant. The overall mean HbA 1c was 7.8% pretransplant and 6.7% posttransplant; this difference was statistically significant (p<0.001). In the 16 patients for whom sufficient data pre-and posttransplant were available on renal outcomes, the median decline in glomular filtration rate (mL/min/mo) was -6.7 pretransplant and -1.3 posttransplant (p=0.01). Retinopathy was assessed using the International Scale, which categorizes nonproliferative diabetic retinopathy as mild, moderate, or severe. Retinopathy progressed in 10 of 82 (12%) eyes pretransplant versus 0 of 51 posttransplant (p<0.01). (The numbers of patients in the retinopathy analyses were not reported). The rate of change in nerve conduction velocity did not differ significantly between groups (exact numbers not reported). The authors noted that their finding of reduced microvascular complications after islet transplantation may be due, in part, to their choice of maintenance immunosuppression. The study used a combination of tacrolimus and mycophenolate mofetil.
Several case series have also been published. These series tend to have small sample sizes and relatively short-term follow-up. Representative series are described next.
In 2013, Rickels et al reported on 12 patients with type 1 diabetes and severe hypoglycemia who had islet transplantation.(10) Mean glycosylated hemoglobin decreased from 7.0%±0.3% before the procedure to 5.6%±0.1% after 6 to 7 months (p<0.01). All of the insulin sensitivity measures were significantly less than normal before islet transplantation and not significantly different from normal after transplantation. Adverse events were not discussed.
In 2013, O'Connell et al reported on 17 patients with type 1 diabetes and severe hypoglycemia who underwent islet transplantation in Australia. (11) The primary end point was the proportion of patients who had had an HbA 1c less than 7% and no severe hypoglycemic events 2 months after the initial transplant. (Patients could have 1 or 2 infusions.) Fourteen of the 17 (82%) patients achieved the primary end point. Nine (53%) patients attained insulin independence for a median of 26 months. At the time of data analysis for this publication, 6 patients remained insulin independent. Most adverse events related to immunosuppression. Seven of the 17 (41%) patients developed mild lymphopenia and 1 developed Clostridium difficile colitis; these all responded to treatment. Eight patients developed anemia shortly after transplant and 1 required a blood transfusion. Procedure-related complications included 1 partial portal vein thrombosis and 3 postoperative bleeds; 2 of the bleeds required transfusion. Patients were followed for different amounts of time; long-term follow-up data were not available for a consistent length of time.
In 2012, Vantyghem et al reported on 23 patients with type 1 diabetes who underwent islet transplantation; 14 had islet-only transplants, and 9 had islet after kidney transplants.(12) Median HbA 1c was 8.3% at baseline and 6.7% at 3 years. Ten of the 23 patients (43%) were insulin independent 3 years after islet transplantation. Findings were not reported separately for the islet-only transplant recipients.
Recent papers have highlighted research in the areas of islet cell regenerative therapy including stemcell technology, encapsulating islets to protect them from the host immune system by a semipermeable capsule, transplantation site, and xenotransplantation. (13) (14) (15) (16) (17) In addition, novel immunosuppressive regimens using biologics have been discussed. (18) Ongoing Clinical Trials A comparison of strict glucose control with usual care at the time of islet cell transplantation (NCT01123122) (19) : This is a single-center randomized controlled trial comparing the impact of strict glucose control versus usual care before islet cell transplantation on outcomes in patients with type 1 diabetes. The primary study outcome is islet cell function 3 months posttransplantation. The estimated enrollment is 32 patients, and the estimated study completion date is September 2015.
Trial Comparing Metabolic Efficiency of Islet Graft to Intensive Insulin Therapy for Type 1 Diabetes's Treatment (TRIMECO) (NCT01148680) (20) : This randomized controlled trial is comparing islet transplantation to intensive insulin therapy in patients with type 1 diabetes. The estimated enrollment is 40 patients, and the estimated study completion date is December 2014.
Summary
Autologous islet transplantation is proposed in conjunction with pancreatectomy for patients with chronic pancreatitis. Although the published experience with autologous islet cell transplantation is limited, the procedure appears to significantly decrease the incidence of diabetes after total or near total pancreatectomy in patients with chronic pancreatitis. In addition, this procedure is not associated with serious complications itself and is performed as an adjunct to the pancreatectomy procedure. Thus, this may be considered medically necessary.
The techniques for allogeneic islet cell transplants are evolving, and the impact on the net health outcome is still uncertain. Moreover, longer follow-up with larger numbers of patients is needed before conclusions can be drawn about the safety of allogeneic islet transplantation and its impact on diabetes mellitus and associated complications. Thus, this technology is considered investigational for patients with diabetes type 1.
Practice Guidelines and Position Statements
Guidance from the National Institute for Clinical Excellence, published in 2008, states that the evidence on allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus shows short-term efficacy with some evidence of long-term efficacy.(21) Evidence on safety shows that serious complications may occur, and the long-term immunosuppression required is also associated with risk of adverse events. The procedure is particularly indicated for patients with hypoglycemia unawareness or those already on immunosuppressive therapy because of renal transplantation. A 2008 update of guidance on autologous islet cell transplantation for improved glycemic control after pancreatectomy states that studies show some short-term efficacy, although most patients require insulin therapy in the long term. Complications mainly result from the major surgery involved in pancreatectomy rather than from the islet cell transplantation. 
